Literature DB >> 2415246

Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.

H S Friedman, S C Schold, D D Bigner.   

Abstract

The continuous human medulloblastoma cell line TE-671 was grown as s.c. and intracranial xenografts in athymic nude mice. Tumor-bearing animals were treated with chemotherapeutic agents at the 10% lethal dose; s.c. xenografts were sensitive to melphalan, 1-(2-chloroethyl)-3-(2,6-dioxo-1-piperidyl)-1-nitrosourea, and 5-azacytidine. No consistent response could be demonstrated to 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate, and no response to methylglyoxal bis(guanyl hydrazone), N-trifluoroacetyl adriamycin-14-valerate, or to 1-beta-D-arabinofuranosylcytosine was observed. Melphalan produced a significant (P = less than or equal to 0.007) increase in the median survival of mice bearing intracranial xenografts, whereas no response was seen to 1-(2-chloroethyl)-3-(2,6-dioxo-1-piperidyl)-1-nitrosourea or 5-azacytidine. This model will allow analysis of the chemotherapeutic profile of human medulloblastoma, and provides a means to differentiate cellular sensitivity and resistance from drug access to the intracranial site.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2415246

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

2.  Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model.

Authors:  L White; K Sterling-Levis; R Fisher; V Tobias
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 3.  The chemotherapy of posterior fossa tumors in childhood.

Authors:  H S Friedman; W J Oakes
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

4.  Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.

Authors:  S X Skapek; A F VanDellen; D P McMahon; D G Postels; O W Griffith; D D Bigner; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors.

Authors:  Stephen T Keir; Mark W Dewhirst; John P Kirkpatrick; Darell D Bigner; Ines Batinic-Haberle
Journal:  Anticancer Agents Med Chem       Date:  2011-02       Impact factor: 2.505

Review 6.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 7.  Embryonal central neuroepithelial tumors: current concepts and future challenges.

Authors:  S R Vandenberg; M M Herman; L J Rubinstein
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

8.  Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat.

Authors:  P A Barnett; S Roman-Goldstein; F Ramsey; C I McCormick; G Sexton; J Szumowski; E A Neuwelt
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

9.  Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain.

Authors:  N H Greig; E M Daly; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.

Authors:  N H Greig; S Genka; E M Daly; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.